The long-term goals of this research are to design, synthesize and evaluate the biological and conformational properties of peptide or peptidomimetic ligands that are highly potent agonists and delta (and kappa) and delta subtype opioid receptors which can cross membrane barriers. In addition, we will design and synthesize ligands that are highly potent and selective for the mu-deltacomplex opioid receptor and mu opioid receptor complexes. These ligands when used alone or in combinations will be used to examine new modalities for analgesia with little or no addiction potential or other undesirable side effects, and to provide new approaches for the treatment of addiction and for withdrawal.
The specific aims to reach these goals include: 1. Using computer assisted drug design methods and biophysical methods to design, synthesize and conformationally evaluate peptide ligands for delta opioid receptor subtypes including the mu-deltacomplex that will be highly efficacious for in vivo analgesia. 2. To use computer assisted methods to design novel ligands related to DPDPE and the deltorphins that interact specifically at the delta1 and delta2 opioid receptors and that will cross the blood brain barrier and other membranes more effectively. 3. To use similar methods as in 2. To design novel analogues of (D- Tca1)CTAP and biphalin that will enable them to more readily cross membrane barriers, especially the blood-brain barrier. 4. Develop systematic approaches to modifying peptides such that they will more readily cross the blood brain barrier. 5. To design analogues with unique biological profiles that can more readily cross the blood brain barrier but that are biotransformed to a more potent and efficacious form. 7. To collaborate with biological colleagues to investigate analogues with ability to be biotransformed to a more active form, that are stable to enzyme degradation, that remain in circulation, etc. 8. To use molecular modeling to design peptidomimetic structures that are more bioavailable but are based on peptide templates.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA006284-05
Application #
3775155
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Remesic, Michael; Macedonio, Giorgia; Mollica, Adriano et al. (2018) Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. Bioorg Med Chem 26:3664-3667
Mowlazadeh Haghighi, Saghar; Zhou, Yang; Dai, Jixun et al. (2018) Replacement of Arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH2, leads to hMC1R selectivity and pigmentation. Eur J Med Chem 151:815-823
Sandweiss, A J; McIntosh, M I; Moutal, A et al. (2018) Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. Mol Psychiatry 23:1745-1755
Bannister, Kirsty; Qu, Chaoling; Navratilova, Edita et al. (2017) Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain 158:2386-2395
Vardanyan, Ruben S; Cain, James P; Haghighi, Saghar Mowlazadeh et al. (2017) Synthesis and Investigation of Mixed ?-Opioid and ?-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain. J Heterocycl Chem 54:1228-1235
Cai, Minying; Marelli, Udaya Kiran; Mertz, Blake et al. (2017) Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists. Biochemistry 56:4201-4209
Hall, Sara M; Lee, Yeon Sun; Hruby, Victor J (2016) Dynorphin A analogs for the treatment of chronic neuropathic pain. Future Med Chem 8:165-77
Deekonda, Srinivas; Cole, Jacob; Sunna, Sydney et al. (2016) Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations. Bioorg Med Chem Lett 26:222-7
Lee, Yeon Sun; Kupp, Robert; Remesic, Michael V et al. (2016) Various modifications of the amphipathic dynorphin A pharmacophore for rat brain bradykinin receptors. Chem Biol Drug Des 88:615-9
Hall, Sara M; LeBaron, Lindsay; Ramos-Colon, Cyf et al. (2016) Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain. ACS Chem Neurosci 7:1746-1752

Showing the most recent 10 out of 268 publications